22. Moyamoya disease Clinical trials / Disease details

Clinical trials : 17 / Drugs : 22 - (DrugBank : 17) / Drug target genes : 33 - Drug target pathways : 45

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04205578 (ClinicalTrials.gov)	January 2020	18/12/2019	NBP in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events	A Multi-center, Randomized, Single-blind, Placebo-controlled Study of Dl-3-n-butylphthalide in Patients With Moyamoya Disease of High Risk for Ischemic Cerebrovascular Events After Extracranial-to-intracranial Revascularization Surgery	Moyamoya Disease;Ischemic Cerebral Infarction;Ischemic Stroke;Ischemic Cerebrovascular Accident;Transient Ischemic Attack	Drug: dl-3-n-butylphthalide (NBP);Drug: Normal Saline 0.9% Infusion Solution	yuanli Zhao	Peking University International Hospital	Not yet recruiting	18 Years	60 Years	All	450	Phase 3	China
2	NCT03882060 (ClinicalTrials.gov)	April 8, 2019	12/3/2019	Effect of Recombinant Human EPO on the Postoperative Neurologic Outcome in Pediatric Moyamoya Patients	The Effect of Recombinant Human Erythropoietin on the Postoperative Neurologic Outcome in Pediatric Moyamoya Disease Patients - A Double Blind Randomized Controlled Trial	Moyamoya Disease;Pediatrics;Cerebrovascular Disorders	Drug: erythropoietin;Drug: Normal saline	Seoul National University Hospital	NULL	Active, not recruiting	N/A	18 Years	All	60	N/A	Korea, Republic of